REFERENCES
- Sodi A, Passerini I, Murro V, et al. BEST1 sequence variants in Italian patients with vitelliform macular dystrophy. Mol Vis 2012;18:2736–2748
- Miller SA, Bresnik GH, Chandra SR. Choroidal neovascular membrane in Best’s vitelliform macular dystrophy. Am J Ophthalmol 1976;86:252–255
- Chung MM, Oh KT, Streb LM, et al. Visual outcome following subretinal hemorrhage in Best disease. Retina 2001;21:575–580
- Viola F, Villani E, Mapelli C, et al. Bilateral juvenile choroidal neovascularization associated with Best’s vitelliform dystrophy: observation versus photodynamic therapy. J Pediatr Ophtalmol Strab 2010;47:121–122
- Frennesson CI, Wadelius C, Nilsson SE. Best vitelliform macular dystrophy in a Swedish family: genetic analysis and a seven-year follow-up of photodynamic treatment of a young boy with choroidal neovascularization. Acta Ophthalmol 2014;92:238–242
- Rich R, Vandervelt S, Berrocal AM, et al. Treatment of choroidal neovascularization associated with Best’s disease in children. J Pediatr Ophthalmol Strabismus 2009;46:306–311
- Ozdek S, Ozmen MC, Tufan HA, et al. Photodynamic therapy for Best disease complicated by choroidal neovascularization in children. J Pediatr Ophthalmol Strab 2012;49:216–221
- Leu J, Schrage NF, Degenring RF. Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2007;245:1723–1725
- Cennamo G, Cesarano I, Vecchio EC, et al. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab. J Ocul Pharmacol Ther 2012;28:643–646
- Marmor MF, Fulton AB, Holder GE, et al. (for the International Society of Clinical Electrophysiology of Vision). ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009;18:69–77
- Marmor MF, Brigell MG, McCulloch DL, et al. (for the International Society of Clinical Electrophysiology of Vision). ISCEV standard for clinical electro-oculography (2010 update). Doc Ophthalmol 2011;122:1–7
- Treatment of Age-Related Macular Degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Arch Ophthalmol 1999;117:1329–1345
- Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541–560
- Anand R, Bressler NM, Bressler SB, et al. “Improvement after Verteporfin therapy.” Writting Committee for TAP Study Group. Arch Ophthalmol 2003;121:415–416
- Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 2003;110:667–673
- Andrade RE, Farah ME, Costa RA. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Best disease. Am J Ophthalmol 2003;136:1179–1181
- Coutinho AM, Silva RM, Nunes SG, et al. Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up. Retina 2011;31:1089–1094
- Rossi S, Testa F, Attanasio M, et al. Subretinal fibrosis in Stargardt’s disease with fundus flavimaculatus and ABCA4 gene mutation. Case Rep Ophthalmol 2012;3:410–417